Janus Kinase Inhibitors - A next generation treatment in Dermatology
DOI:
https://doi.org/10.66344/jpad.v31i4.1777Abstract
Over the past few decades, drugs targeting cytokines and their receptors have been researched and developed. These agents act on molecular targets at the subcellular level. The Janus Kinases family is a group of receptor-associated signaling molecules which are essential to the signal cascade originating from Type 1 and Type 2 cytokine receptors. Janus kinase inhibitors, also known as Jakinibs/ JAK inhibitors, are molecules developed against this class of kinases. Initially developed for use in different inflammatory conditions, such as rheumatological problems, JAK inhibitors are emerging as new agents in dermatology. Although biologics have proved to be effective and safe in various disorders, not all patients respond to this therapy. Jakinibs are also being seen as an alternative oral therapy for such patients. This article will review the basic principles of mode of action, efficacy and safety of JAK inhibitors in autoimmune conditions such as psoriasis, alopecia areata, atopic dermatitis, lupus erythematosus, dermatomyositis and vitiligo.
References
1. Heymann WR. “TOFACITINIB: A JAK INHIBITOR OF ALL TRADES.” 2019 DW Insights and Inquiries Archive, American Academy of Dermatology Association, 3 Apr.2019;1(4).
2. Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol.2019;10:2342. doi:10.3389/fimmu.2019.02342
3. Cinats A, Heck E, Robertson L. Janus kinase inhibitors: A review of their emerging applications in dermatology. Skin Ther Lett. 2018;23:5-9.
4. Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019 Nov;30(7):648-658. doi: 10.1080/09546634.2018.1546043. Epub 2018 Dec 3. PMID: 30433838.
5. Bubna AK. Janus Kinase Inhibitors in Dermatology. Indian J Drugs Dermatol. 2019;5:6-13.
6. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey. Leukemia.2015;29:2062-8.
7. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol.2017;76(4):736-44. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28. PMID: 28139263; PMCID: PMC6035868.
8. P.J. Murray. The JAK-STAT signaling pathway: input and output integration. J Immunol.2007;178(5):2623–29.
9. K. Ghoreschi and M. Gadina. JAKpot! new small molecules in autoimmune and inflammatory diseases. Exp Dermat.2014; 23(1):7–11.
10. K. Ortiz-Ibanez, M. M. Alsina, and C. Munoz-Santos. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermo-Sifiliográficas.2013;104(4):304–10.
11. Leeyen Hsu, April W. Armstrong, JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. J Immunol Res.2014;2014:283617.
12. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, and O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev.2008;223(1):132-42.
13. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol.2016;74(5):841-50.
14. Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol.2015;173(4):949-61.
15. Bachelez H, van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee JH et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet.2015;386(9993):552-61.
16. Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017;77(1):79-87.
17. Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaichet C et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol.2016;174(6):1266-76.
18. Ludbrook VJ, Hicks KJ, Hanrott KE , Patel JS, Binks MH, Wyres MR et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebocontrolled phase IIa study. Br J Dermatol.2016;174(5):985-95.
19. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol.2013;169(1):137-45.
20. Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P et al. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173(4):989-97.
21. Pfizer announces FDA approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the treatment of active psoriatic arthritis [Internet]. Pfizer Pharmaceutical News and Media. Press release dated December 14, 2017. Accessed March 31, 2018.
22. Mease P, Hall S, FitzGerald O, Van Der Heijde D, Merola JF, Avila-Zapata F et al. Tofacitinib or Adalimumab versus placebo for psoriatic arthritis. N Engl J Med.2017;377(16):1537-50.
23. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszu A et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med.2017; 377(16):1525-36.
24. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol.2015;73(3):395- 9.
25. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol.2016;175(5):902-11.
26. Kranseler, J, Sidbury, R. Alopecia areata: update on management. Indian J Paediatr Dermatol.2017;18(4):261-6.
27. Gilhar A, Schrum A, Etzioni A, Waldmann H, Paus R. Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. Autoimmun Rev.2016;15(7):726-35.
28. Xing L, Dai Z, Jabbari A. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-49.
29. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers.2017;3:17011. doi:10.1038/nrdp.2017.11.
30. Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110-12.
31. Bishnoi A, Parsad D. Clinical and Molecular Aspects of Vitiligo Treatments. Int J Mol Sci.2018;19(5):1509.
32. Kurtzman DJ, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: An alternative treatment. JAMA Dermatol. 2016;152:944-5.
33. Yang CC, Khanna T, Sallee B, Christiano AM, Bordone LA. Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther.2018;31:e12656.
34. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D et al. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. J Invest Dermatol. 2016;136(6):1281-83.
doi: 10.1016/j.jid.2016.02.015.
35. Van Vollenhoven RF, Layton M, Kahl L, Schifano L, Hachulla E, Machado D et al. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus.2015;24(6):648-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Nadia Ali Azfar, Sadaf Ibrahim, Muhammad Nadeem
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
